The increased breast mammographic density as an adverse effect of menopausal hormonal therapy

Tomasz Paszkowski; Tomasz Pertyński; Andrzej Drop; Janusz Jaśkiewicz

Abstract

2/2006 vol. 5

The increased breast mammographic density as an adverse effect of menopausal hormonal therapy

Tomasz Paszkowski

,

Tomasz Pertyński

,

Andrzej Drop

,

Janusz Jaśkiewicz

Prz Menopauz 2006; 2: 109–115

Online publish date: 2006/05/12

View full text

AMA

Paszkowski T, Pertyński T, Drop A, Jaśkiewicz J. The increased breast mammographic density as an adverse effect of menopausal hormonal therapy. Menopause Review/Przegląd Menopauzalny. 2006;5(2):109-115.

APA

Paszkowski, T., Pertyński, T., Drop, A., & Jaśkiewicz, J. (2006). The increased breast mammographic density as an adverse effect of menopausal hormonal therapy. Menopause Review/Przegląd Menopauzalny, 5(2), 109-115.

Chicago

Paszkowski, Tomasz, Tomasz Pertyński, Andrzej Drop, and Janusz Jaśkiewicz. 2006. "The increased breast mammographic density as an adverse effect of menopausal hormonal therapy". Menopause Review/Przegląd Menopauzalny 5 (2): 109-115.

Harvard

Paszkowski, T., Pertyński, T., Drop, A., and Jaśkiewicz, J. (2006). The increased breast mammographic density as an adverse effect of menopausal hormonal therapy. Menopause Review/Przegląd Menopauzalny, 5(2), pp.109-115.

MLA

Paszkowski, Tomasz et al. "The increased breast mammographic density as an adverse effect of menopausal hormonal therapy." Menopause Review/Przegląd Menopauzalny, vol. 5, no. 2, 2006, pp. 109-115.

Vancouver

Paszkowski T, Pertyński T, Drop A, Jaśkiewicz J. The increased breast mammographic density as an adverse effect of menopausal hormonal therapy. Menopause Review/Przegląd Menopauzalny. 2006;5(2):109-115.

The influence of menopausal hormonal therapy (HT) on the breast remains one of the crucial aspects of the menopausal medicine. In this context the jatrogenic deterioration of the mammographic examination sensitivity due to the increased mammographic breast density (MBD) gains special importance. This problem is analyzed in the paper from the multidisciplinary point of view of a gynecologist, radiologist and a surgeon. The increased MBD in the course of HT constitutes an extremely important clinical problem which is currently being widely discussed worldwide. The high MBD affects the breast cancer risk, hampers the interpretation of the mammographic examination and decreases both the specificity and sensitivity of mammography. Tibolone and transdermal estro-progestagenic therapy increase the MBD to a significantly lower degree than the oral HT.